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uniklinik-freiburg.deAbstractA third of patients with paraganglial tumors, pheochromocytoma, and paraganglioma, carry
germline mutations in one of the susceptibility genes, RET, VHL, NF1, SDHAF2, SDHA, SDHB,
SDHC, SDHD, TMEM127, and MAX. Despite increasing importance, data for long-term
prognosis are scarce in pediatric presentations. The European-American-Pheochromocytoma–
Paraganglioma-Registry, with a total of 2001 patients with confirmed paraganglial tumors,
was the platform for this study. Molecular genetic and phenotypic classification and
assessment of gene-specific long-term outcome with second and/or malignant paraganglial
tumors and life expectancy were performed in patients diagnosed at !18 years. Of 177
eligible registrants, 80% had mutations, 49% VHL, 15% SDHB, 10% SDHD, 4% NF1, and one
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21 :1 1838% with increasing frequency over time, reaching 50% at 30 years after initial diagnosis.
Their prevalence was associated with hereditary disease (PZ0.001), particularly in VHL and
SDHD mutation carriers (VHL vs others, PZ0.001 and SDHD vs others, PZ0.042). A total of
16 (9%) patients with hereditary disease had malignant tumors, ten at initial diagnosis and
another six during follow-up. The highest prevalence was associated with SDHB (SDHB vs
others, P!0.001). Eight patients died (5%), all of whom had germline mutations. Mean life
expectancy was 62 years with hereditary disease. Hereditary disease and the underlying
germline mutation define the long-term prognosis of pediatric patients in terms of
prevalence and time of second primaries, malignant transformation, and survival. Based on
these data, gene-adjusted, specific surveillance guidelines can help effective preventive
medicine.http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0415 Printed in Great Britain
Published by Bioscientifica Ltd.
DownloadedEndocrine-Related Cancer
(2014) 21, 17–25IntroductionPheochromocytomas and paragangliomas are tumors of
the overall paraganglial system, mainly the adrenal
glands, the retroperitoneum, the pelvis, the thorax, and
the skullbase and neck regions (Neumann 2008). Such
paraganglial tumors occur at any age, from early
childhood until late in life with mean age at diagnosis
w40 years. Their clinical presentation is historically
characterized by the ‘rule of tens’: 10% of pheochromo-
cytomas are bilateral, 10% extraadrenal, and 10% malig-
nant. Paraganglial tumors confer high morbidity and
mortality. Their diagnosis provides a correctable cause of
hypertension and can prevent life-threatening compli-
cations such as heart failure and arrhythmias. Over one-
third of all patients with paraganglial tumors carry
germline mutations in one of the ten susceptibility
genes: VHL, RET, NF1, SDHAF2, SDHA, SDHB, SDHC,
SDHD, MAX, and TMEM127 (Neumann et al. 2002, 2004,
Mannelli et al. 2007, 2009, Bayley et al. 2010, Burnichon
et al. 2010, Qin et al. 2010, Comino-Mendez et al. 2011).
Mutations in these genes cause pheochromocytoma-
associated cancer syndromes such as von Hippel-Lindau
disease (VHL), multiple endocrine neoplasia type 2
(MEN2), neurofibromatosis type 1 (NF1), the paragan-
glioma syndrome types 1–4 (PGL1–4), and the familial
pheochromocytoma syndromes. Patients with hereditary
pheochromocytoma have a lifelong risk of second
paraganglial tumors and relapse and frequently have life-
threatening, syndrome-specific, extraparaganglial tumors,
such as hemangioblastomas of the retina and CNS in VHL,
medullary thyroid carcinoma in MEN2, and renal cell
carcinoma in VHL, PGL1, PGL3, and PGL4 (Asari et al.
2006, Khorram-Manesh et al. 2006, Timmers et al. 2008,
Grubbs et al. 2013). Early onset of disease, bilateral,multifocal, extraadrenal, and malignant tumors are the
clinical hallmarks of hereditary disease (Neumann et al.
2002). Over the last decade, numerous studies have
discovered the molecular basis and clinical characteristics
of pheochromocytoma and paraganglioma. The insights
into their etiopathogenesis and phenotypic characteristics
help to reduce their morbidity and mortality by the
possibility of a more efficient and gene-specific tailored
preventive medical management. However, the subgroup
of pediatric pheochromocytoma is poorly studied, despite
their important clinical consequences. Approximately
20% of pheochromocytomas and paragangliomas are
diagnosed in children, predominantly males (Stackpole
et al. 1963, Kaufman et al. 1983, Ciftci et al. 2001, Barontini
et al. 2006). Children usually suffer from symptomatic and
potentially life-threatening occurrence with bilateral and
extraadrenal tumors (Stackpole et al. 1963, Ein et al. 1990,
Ciftci et al. 2001, Barontini et al. 2006). Prevalence of
hereditary and malignant tumors is controversial, but of
utmost importance for quality-of-life considerations and
survivorship (Ross 2000, Barontini et al. 2006, De Krijger
et al. 2006, Pham et al. 2006, King et al. 2011). So far, no
data from large population-based registries or long-term
surveillance are available. Reports focused on pediatric
patients are mostly based on few cases (Stackpole et al.
1963, Kaufman et al. 1983, Ein et al. 1990, Ross 2000, Ciftci
et al. 2001, Barontini et al. 2006, De Krijger et al. 2006,
Pham et al. 2006, King et al. 2011). Therefore, we sought to
systematically perform molecular and clinical character-
ization of pediatric pheochromocytoma and paragan-
glioma to determine the long-term prognosis and
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Patients
The platform of this study was the European-American-
Pheochromocytoma–Paraganglioma-Registry based in
Freiburg/Germany with a total of 2001 patients histo-
logically confirmed with symptomatic paraganglial
tumors. Inclusion criteria were age at initial diagnosis
younger than 18 years and EDTA-anticoagulated blood
available for genetic testing. In cases of several tumors, the
youngest age at diagnosis was used. Patients who initially
presented with syndrome-associated features and/or a
known family history were also included. We excluded
relatives in whom paraganglial tumors were diagnosed by
family screening at an asymptomatic stage. All patients
provided written informed consent.
Molecular genetic analysis
EDTA-anticoagulated blood leucocyte genomic DNA was
analyzed for mutations in RET (MEN2), VHL, NF1,
SDHAF2, SDHB, SDHC, SDHD (PGL1–4), and the new
genes TMEM127, MAX, and SDHA (familial pheochromo-
cytoma syndromes). In addition, an investigation of large
deletions was carried out in VHL, NF1, SDHB, SDHC, and
SDHD. Mutation scanning was performed by denaturing
HPLC using the WAVE analysis system and by
bidirectional Sanger sequencing. Large deletions and
duplications were sought by quantitative real-time PCR
with SYBR Green I detection and by multiplex ligation
probe amplification (MLPA) assays. Genomic DNA
samples from 100 anonymous, healthy blood donors
were analyzed as matching controls.Clinical studies
All registrants provided demographic and clinical
information including gender, age at diagnosis, symp-
toms, biochemical, and imaging data as well as family
health histories. Paraganglial tumors were classified
according to tumor number (solitary or multiple), location
(adrenal, extraadrenal abdominal, thoracic, head, and
neck), and biology (benign or malignant) (Table 1).
Criteria for malignancy were presence of metastases in
lymph nodes or distant tissues (Tischler 2008). Patients
who were identified as having one of the hereditary
syndromes underwent clinical reevaluation. The clinical
screening program comprised for MEN2 serum calcitonin
and parathormone, for VHL magnetic resonance imaging
(MRI) of the CNS, MRI of the abdomen and retinoscopy,http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0415 Printed in Great Britainand for the paraganglioma syndromes (PGL1–4) MRI of
the abdomen, thorax, and neck.
All patients were provided a follow-up clinical
investigation. These included surveillance to detect new
tumors, e.g. second paraganglial tumors, extraparaganglial
tumors, and malignant transformation. Second tumors
were classified as ipsilateral tumors, tumors of the
contralateral adrenal gland, and of extraadrenal origin.
The frequency of second tumors and gene-specific
differences was evaluated. Finally, age and causes of
death were documented.Statistical analysis
Categorical variables were expressed as absolute and
relative frequencies and compared by two-sided c2 test.
Scale variables were expressed as median and range and
compared by two-sided Mann–Whitney U test. Censored
data were analyzed and plotted by Kaplan–Meier method
and compared by two-sided log-rank test. The 95% CI for
proportions was calculated according to the modified
method of Wilson by Newcombe (Wilson 1927,
Newcombe 1998). Significance level was set to PZ0.05
for statistical testing. All statistical calculations were
carried out with IBM SPSS, version 17 (SPSS, Inc.).Results
As of July 1, 2013, the European-American-Pheochromo-
cytoma–Paraganglioma-Registry comprised 2001 regis-
trants with symptomatic paraganglial tumors. Of these
2001 registrants, 177 (9%) were diagnosed !18 years.
There were 164 unrelated index cases and 13 first- or
second-degree relatives of the index cases. Age distribution
at initial diagnosis was 4–17 years, with mean 13 years
(95% CI 12–13), with 116 males and 61 females (Table 1).
Among the 164 index patients, 105 patients (64%)
presented with apparently sporadic disease, whereas 51
patients (31%) had a positive family history for para-
ganglial tumors. Six patients presented with neurofibro-
mas and thus met diagnostic criteria for NF1. Ten patients
were identified as having the prototypic lesions of VHL-
disease, retinal hemangioblastoma, and/or hemangioblas-
toma of the CNS.
The 164 (94%) index patients were symptomatic and
had hypertension, palpitations, headache, or profuse
sweating. The diagnosis was clinically confirmed by
elevated catecholamines or metanephrines and by radio-
logical imaging. Elevated values of 24 h-urinary catechol-
amines, metanephrines, and of plasma metanephrinesPublished by Bioscientifica Ltd.
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21 :1 21were recorded in 101 (89%) patients. Head and neck
paragangliomas (HNPs) were identified in 8 (5%) patients.
There were 43 (24%) patients with bilateral adrenal tumors
and 53 (30%) with extraadrenal tumors. Ten (6%) patients
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Figure 1
Overview of the gene-specific follow-up in years considering the period of
time from initial diagnosis up to July 1, 2013. The black vertical line
indicates the mean follow-up, the box includes time range of 50% of all
cases and the whiskers present the 95% CI. Patients harboring a SDHA-,
SDHC- and RET-mutation are summarized as rare/other mutation carriers.
They were only observed in single cases. The mean follow-up interval was
16 years. The mean, gene-specific follow-up was 10 years (range 1–45) for
sporadic patients, 19 years (range 0–53) for VHL, 10 years (range 1–42) for
SDHB, 13 years (range 4–46) for SDHD, 11 years (range 2–12) for NF1, and
13 years (range 12–13) for other/rare mutation carriers.Molecular genetic characterization
Of the 164 index patients, 131 (80%) had a germline
mutation in one of the susceptibility genes, of which
80 (49%) were VHL, 25 (15%) SDHB, 17 (10%) SDHD, and
6 (4%) NF1. Mutations of RET and of the new susceptibility
genes, SDHC and SDHA, were observed in one patient
each. Mutations of SDHAF2, MAX, and TMEM127 were not
present in this cohort. Of 131 different mutations, 123
were found within the exons, namely missense mutations,
stop codon mutations, small deletions or insertions. Eight
mutations (6%) were large deletions encompassing 1–3
exons. All eight deletions affected the SDH-genes, SDHB,
SDHC, and SDHD.
Patients with sporadic (nZ33) and hereditary (nZ144)
paraganglial tumors did not differ in their mean age at
initial diagnosis of 13 years of age (PZ0.8). But hereditary
paraganglial tumors caused by VHL mutations occurred
earlier in childhood than those caused by SDHB and NF1
(PZ0.001 and PZ0.026) and with a trend compared with
SDHD (PZ0.07) (Table 1). Bilateral adrenal tumors
occurred significantly more frequent in VHL mutation
carriers than in SDHB or SDHD mutations carriers or
patients with sporadic disease (P!0.001). Extraadrenal
tumors were significantly more often associated with
SDHB and SDHD mutations (SDHB vs others, P!0.001
and SDHD vs others, PZ0.029). Thoracic paraganglial
tumors (nZ9) were mostly associated with SDHD
mutations (SDHD vs others, P!0.001). At initial diagnosis,
10 (6%) registrants had malignant paraganglial tumors
and most of them had SDHB (SDHB vs others, PZ0.005).
HNPs were mostly hereditary and caused by SDHD
mutations (SDHD vs others, P!0.001; Table 1).
Long-term surveillance
Follow-up data were available for 5 years in 78% and for
10 years in 48% of the registrants (Fig. 1). Of the 177
registrants, 68 (38%) developed second paraganglial
tumors after a mean interval of 25 years. Incidence of
second tumors increased with time from 25% at 9 years to
50% at 31 years (Fig. 2A). Seventeen (16%) patients had an
ipsilateral tumor. Twenty-one (13%) had a second
contralateral adrenal tumor and 28 (18%) second extra-
adrenal paraganglial tumor. Fifteen of the 17 patients withhttp://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0415 Printed in Great Britainipsilateral tumors developed another contralateral or
extraadrenal tumor. Contralateral and extraadrenal
tumors occurred more often than ipsilateral ones (95%
CI 31–46 vs 13–28%). However, the period of latency did
not differ in the three groups.
Second paraganglial tumors were significantly more
common in hereditary than in sporadic disease (PZ0.001).
Ipsilateral tumors and third paraganglial tumors were
exclusively associated with hereditary disease without
gene-specific differences in frequency. Notably, second
contralateral adrenal and extraadrenal tumors were more
often associated with VHL and SDHD mutations (VHL vs
others, PZ0.001 and SDHD vs others, PZ0.042; Table 2).
Second tumors occurred 10 years earlier in hereditary than
in sporadic disease (period of latency 23 vs 33 years
respectively, PZ0.031). The time to second tumors
showed gene-specific differences with the shortest latency
in SDHD and VHL with 18 and 21 years (SDHD vs sporadic,
PZ0.01 and VHL vs sporadic, PZ0.01; Fig. 2B).
HNPs as a second tumor were observed in 7 (4%)
patients. There was no difference in the period of latency
among ipsilateral, contralateral, and extraadrenal para-
ganglial tumors compared with HNPs. HNPs were mostly
caused by SDHD mutations at initial diagnosis (SDHD vs
others, P!0.001) and during follow-up (SDHD vs others,
PZ0.002) (Table 2).Published by Bioscientifica Ltd.
Downloaded from Bioscientifica.com at 06/10/2021 07:15:42AM
via free access



















































Years after first tumor
Figure 2
(A) Time-related prevalence of second paraganglial tumors. A total of
68 patients experienced a second paraganglial tumor. Ipsilateral tumors
were observed in 17 (16%) patients. Contralateral pheochromocytomas
were observed in 21 (13%) and extraadrenal pheochromocytomas were
observed in 28 (18%) patients. The percentage increased by time reaching
25% 9 years and 50% 31 years after initial diagnosis. (B) Time-related, gene-
specific prevalence of second paraganglial tumors. Four (12%) sporadic,
46 (50%) VHL, 6 (24%) SDHB, 10 (59%) SDHD, 1 (17%) NF1, and 1 (33%) RET
patient experienced a second paraganglial tumor. Mean period of time
after initial diagnosis was 33 years in sporadic and 23 years in hereditary
patients. Mean period of time after initial diagnosis was 21 years in VHL,
30 years in SDHB, 18 years in SDHD, and 12 years in NF1. Patients with
hereditary disease experienced significantly earlier second paraganglial
tumors than sporadic patients. As for the different genes no significant
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interval from detection of the second to the third
tumor was 1–20, mean 5 years. All these patients had a
germline mutation.http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0415 Printed in Great BritainMalignant paraganglial tumors were initially present
in 10 (6%) patients. During follow-up six additional
patients (4%) were identified with metastases. Of these
six patients, four showed metastases up to 7 years after the
initial/last operation. Mutations were present in the genes
VHL, RET, NF1, SDHB and SDHD. SDHB mutation-positive
individuals had the highest prevalence of malignancy
(SDHB vs others, P!0.001; Table 2). Additional risk factors
for malignant disease were extraadrenal and thoracic
paraganglial tumors (extraadrenal: PZ0.027, OR 3.6 and
thoracic: PZ0.002, OR 10.27).
Extraparaganglial tumors were only seen in mutation
carriers, mostly of VHL. Forty percent of the VHL patients
had retinal angiomas, 31% hemangioblastomas of the
CNS, 4% renal cell carcinomas, and 12% pancreatic
neuroendocrine tumors. One SDHB mutation carrier
presented with renal cell carcinoma and one with
papillary thyroid carcinoma. One RET mutation carrier
developed a medullary thyroid carcinoma.
Eight of the 177 patients died. All had hereditary
diseases, threeVHL, threePGL4 syndrome (SDHB), oneNF1,
and one SDHA-associated disease. The causes of death were
cardiac failure in one and metastases in seven patients.
Life expectancy in hereditary disease was 62 years
(mean), but remarkably reduced in patients with SDHB and
NF1 mutations (SDHB vs others, PZ0.009; SDHB vs VHL,
PZ0.012; and NF1 vs VHL, PZ0.008) (Fig. 3 and Table 2).Discussion
The multidisciplinary interrogation of hereditary neo-
plasia syndromes has enriched our insights into the
pathogenesis of both heritable and sporadic carcinogen-
esis and gene-enabled clinical management. In cancer
syndromes, these insights are essential for the develop-
ment of targeted therapies and for the establishment of
gene-specific surveillance guidelines, the cornerstone for
increasing life expectancy and improving quality of life.
Data are plentiful from the adult-onset side, but rare from
systematic study of gene-specific clinical outcomes of
pediatric neuroendocrine presentations. Paradoxically,
very little is known about pediatric-onset pheochromocy-
toma and paraganglioma, given that the load of genetic
disease in childhood-onset neoplasias should be high. This
study presents molecular classification of pediatric-onset
pheochromocytoma and paraganglioma with mutational
and phenotypic spectra and especially, gene-associated
long-term clinical outcome.
In contrast to a 30% mutation frequency in adults, we
have shown that 80% of 177 pediatric presentations havePublished by Bioscientifica Ltd.
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Gene-specific survival. Survival in years of VHL-, SDHB-, and NF1-affected
patients. A total of 8 (5%) patients died. All patients were affected by
hereditary disease, 3 (3%) VHL carriers, 3 (12%) SDHB carriers, 1 (17%)
NF1 carrier, and one SDHA carrier. No pediatric patient with sporadic and
SDHD-associated pheochromocytoma died during the follow-up period.
Mean life expectancy in hereditary disease was 62 years. Life expectancy in
VHL was 64 years, whereas patients carrying SDHB had a shorter mean
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This population-based frequency was even higher than
expected compared with published data from smaller
pediatric series of 22–70% (Ciftci et al. 2001, Neumann
et al. 2002, Barontini et al. 2006, De Krijger et al. 2006,
Cascon et al. 2013). The affected genes are dominated by
VHL followed by SDHB, SDHD, and NF1. Predominance of
VHL mutations was identified by us previously and
confirmed by others (Neumann et al. 2002, Barontini
et al. 2006, Bausch et al. 2006a). The phenotypic
presentation is characterized by multiple, mostly bilateral
adrenal and extraadrenal tumors (Ciftci et al. 2001,
Barontini et al. 2006).
The paramount implication of the high prevalence of
germline mutations is the question of adequate follow-up.
General agreement exists that there is a lifelong risk for the
development of new tumors. Specific data are however
scarce. This includes questions regarding gene-specific
differences associated with potential transformation to
malignant behavior of the disease (Ein et al. 1990, Ciftci
et al. 2001, Beltsevich et al. 2004, Asari et al. 2006,
Barontini et al. 2006, Khorram-Manesh et al. 2006,
Timmers et al. 2008, King et al. 2011, Grubbs et al. 2013).
Our data emphasizes the need for meticulous short-
and long-term follow-up. Tumor recurrences occur early,http://erc.endocrinology-journals.org q 2014 Society for Endocrinology
DOI: 10.1530/ERC-13-0415 Printed in Great Britainwithin the first year, but they can occur 30 years after
primary surgery (Fig. 2A). Ten percent develop malignant
paraganglial tumors with 40% presenting after years. This
underscores the importance of long-term surveillance
and vigilance especially in patients with VHL, SDHB, or
SDHD mutations.
Catecholamine storms with consequent heart failure
or stroke and metastases are the major factors for reduced
life expectancy in paraganglial tumors, at least in adult
series. Here we see that this is rare, but we found that life
expectancy is mainly influenced by malignant behavior of
the disease (Fig. 3). Patients, with SDHB mutations,
predominantly die because of metastatic disease (King
et al. 2011). It is noteworthy that life expectancy is greatly
reduced in 70% of the patients with an SDHB mutation.
Thus, pediatric presentations with SDHB mutations must
be aggressively followed. In time, targeted preventative or
adjuvant therapies may be available for such patients
relatively early.
Our results suggest general and gene-specific
recommendations for adequate care of patients with
paraganglial tumors diagnosed under the age of 18 years.
First, all such patients need analysis for germline
mutations in the susceptibility genes for such tumors,
especially VHL, SDHD, and SDHB. NF1 can be diagnosed
clinically, but careful skin investigation is important
(Bausch et al. 2006b). Second, all ‘high-risk’ patients
should be offered surveillance, in particular mutation
carriers. Third, annual surveillance is recommended for
the first 3 years after initial diagnosis, because this is the
period when malignant behavior becomes mostly evident,
if not diagnosed initially already. Fourth, as recurrent
tumors are mostly seen in carriers of VHL and SDHD
mutations, such patients need close and on-going high-
risk surveillance, which should be done every 3 years after
yearly checks in the years 1–3 after operation because of
lower but continuous risk of malignancy.
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